In tolvaptan-treated ADPKD patients, the reduction in p22phox protein levels not only suggests reduced OxSt, but also, given its presence in leukocytes, an inhibition of leukocyte activation, a well-known cause of OxSt in CKD. The gene discussed is CYBA; the disease is autosomal dominant polycystic kidney disease.